Biomedical Engineering Reference
In-Depth Information
403. Hagenbuch N, Reichel C, Stieger B, Cattori V, Fattinger KE, Landmann L, Meier PJ,
Kullak-Ublick GA. 2001. Effect of phenobarbital on the expression of bile salt and
organic anion transporters of rat liver. J Hepatol 34: 881-887.
404. Johnson DR, Habeebu SS, Klaassen CD. 2002. Increase in bile flow and biliary excretion
of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is
mediated by multidrug resistance protein 2. Toxicol Sci 66: 16-26.
405. K onig J, Nies AT, Cui Y, Leier I, Keppler D. 1999. Conjugate export pumps of the
multidrug resistance protein (MRP) family: localization, substrate specificity, and
MRP2-mediated drug resistance. Biochim Biophys Acta 1461: 377-394.
406. Sathirakul K, Suzuki H, Yasuda K, Hanano M, Tagaya O, Horie T, Sugiyama Y. 1993.
Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic
mutant rats. J Pharmacol Exp Ther 265: 1301-1312.
407. Kusuhara H, Suzuki H, Sugiyama Y. 1998. The role of P-glycoprotein and canalicular
multispecific organic anion transporter in the hepatobiliary excretion of drugs. J Pharm
Sci 87: 1025-1040.
408. Sasabe H, Tsuji A, Sugiyama Y. 1998. Carrier-mediated mechanism for the biliary ex-
cretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol
Exp Ther 284: 1033-1039.
409. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y. 1997. Biliary excretion
of pravastatin in rats: contribution of the excretion pathway mediated by canalicular
multispecific organic anion transporter. Drug Metab Dispos 25: 1123-1129.
410. Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H,
Sugiyama Y. 1997. Methotrexate is excreted into the bile by canalicular multispecific
organic anion transporter in rats. Cancer Res 57: 3506-3510.
411. Lalloo AK, Luo FR, Guo A, Paranjpe PV, Lee SH, Vyas V, Rubin E, Sinko PJ. 2004
Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1)
and multidrug resistance protein 2 (ABCC2). BMC Med 2: 16.
412. Luo FR, Paranjpe PV, Guo A, Rubin E, Sinko P. 2002. Intestinal transport of irinotecan
in Caco-2 cells and MDCKII cells overexpessing efflux transporters Pgp, cMOAT, and
MRP1. Drug Metab Dispos 30: 763-770.
413. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock
MK, Donehower RC. 1994. Phase I and pharmacological study of the novel topoiso-
merase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin
(CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54: 427-
436.
414. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A. 1993. Relationship between
development of diarrhea and the concentration of SN-38, an active metabolite of
CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal
administration of CPT-11. Jpn J Cancer Res 84: 697-702.
415. Sugiyama Y, Kato Y, Chu X. 1998. Multiplicity of biliary excretion mechanisms for the
camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide:
role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer
Chemother Pharmacol 42 (Suppl): S44-S49.
416. Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y. 1997. Multispecific
organic anion transporter is responsible for the biliary excretion of the camptothecin
derivative irinotecan and its metabolites in rats. J Pharmacol and Exp Ther 1: 304-314.
Search WWH ::
Custom Search